Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer
Brief Summary: This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen


Options:
A: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab), Drug: Tremelimumab | Arm Label: Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 (Durvalumab) | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Combination Therapy, Monotherapy | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Standard of Care
B: Arm Label: Arm N - Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N-I, Level 1: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2b: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2c: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm N - Nivolumab, Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib
C: Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab
D: Arm Label: Tislelizumab; Type: EXPERIMENTAL; Interventions: Drug: Tislelizumab | Intervention Type: DRUG; Name: Tislelizumab; Assigned to Arm(s): Tislelizumab

Answer: D